Oxford Genetics specializes in advanced technologies for the development and manufacturing of cell and gene therapies, focusing on accelerating the transition from laboratory research to clinical applications. Their offerings include a range of solutions such as promoter discovery services, plasmids, and cell lines, as well as transient production systems for lentiviral (LV) and adeno-associated viral (AAV) vectors. A key innovation is their TESSA™ technology, which utilizes self-silencing adenoviral vectors to enhance the production of high-quality AAV. This technology allows for scalable and efficient AAV manufacturing while minimizing contamination and improving yield and infectivity, making it a valuable tool for gene therapy pioneers.

In addition to TESSA™, Oxford Genetics emphasizes the importance of optimizing gene expression through the discovery of novel promoters tailored to specific therapeutic needs. Their bioinformatics-driven approach enables the design of synthetic promoter libraries that can be fine-tuned for precise control over transgene expression, thereby reducing the risk of off-target effects and toxicity. By leveraging these advanced technologies, Oxford Genetics aims to support pioneering companies in delivering breakthrough cell and gene therapies to patients in need, ultimately enhancing the efficacy and safety of these innovative treatments.

United Kingdom

Oxford Genetics is a synthetic biology company focused on developing novel technologies to overcome challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

Oxford Genetics

Company Details